Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Gross Margin (2020 - 2022)

Historic Gross Margin for Immuneering (IMRX) over the last 3 years, with Q4 2022 value amounting to 100.0%.

  • Immuneering's Gross Margin rose 1087700.0% to 100.0% in Q4 2022 from the same period last year, while for Sep 2023 it was 100.0%, marking a year-over-year increase of 719900.0%. This contributed to the annual value of 50.11% for FY2022, which is 55500.0% up from last year.
  • According to the latest figures from Q4 2022, Immuneering's Gross Margin is 100.0%, which was up 1087700.0% from 49.6% recorded in Q3 2022.
  • Over the past 5 years, Immuneering's Gross Margin peaked at 100.0% during Q4 2022, and registered a low of 8.77% during Q4 2021.
  • For the 3-year period, Immuneering's Gross Margin averaged around 47.78%, with its median value being 50.55% (2022).
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -376200bps in 2021, then skyrocketed by 1087700bps in 2022.
  • Over the past 3 years, Immuneering's Gross Margin (Quarter) stood at 28.85% in 2020, then plummeted by -130bps to 8.77% in 2021, then surged by 1240bps to 100.0% in 2022.
  • Its last three reported values are 100.0% in Q4 2022, 49.6% for Q3 2022, and 49.23% during Q2 2022.